ArticleInternational journal of molecular sciences2025
Identification of a Prognostic ceRNA Network Regulating TMBIM6 in Prostate Adenocarcinoma via Integrated Bioinformatic Analysis.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
TMBIM6, a transmembrane BAX inhibitor motif containing six proteins, is correlated with tumor progression and metastasis. While its correlation in several malignancies has been shown, its expression in prostate adenocarcinoma (PRAD) is unclear. In this work, we explored, using integrated bioinformatics, a novel ceRNA network of TMBIM6 involved in PRAD prognosis. According to TCGA and GEO datasets, we proposed a new TMBIM6/hsa-miR-222-3p/DHRS4-AS1 ceRNA axis associated with PRAD prognosis. The network was estimated by differential expression, correlation, and survival analysis. Co-expression analysis was used to identify pathways involved in tumor progression, and immune infiltration analysis suggested that there is a correlation between the expression of TMBIM6 and the abundance of epithelial cells. Overall, these results indicate that the DHRS4-AS1/hsa-miR-222-3p/TMBIM6 axis is involved in the progression of PRAD and may act as a prognostic biomarker. Our results provide a foundation for further experimental validation and potential clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.